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New generation VMAT2 inhibitors induced
parkinsonism
1. Introduction
Tardive syndrome (TS), is one of the most common drug‐induced
movement disorders. TS is primarily caused by the prolonged use of
dopamine‐blocking agents such as antipsychotics. Tetrabenazine is
vesicular monoamine transporter type 2 (VMAT‐2) inhibitor which
is FDA approved for chorea in Huntington’s disease and also used
off‐label for TS. VMAT‐2 inhibitors deplete monoamines such as dopa-
mine, norepinephrine, serotonin, and histamine and are expected to
reduce dyskinetic movements by reducing dopamine neurotransmis-
sion. However, tetrabenazine use is currently discouraged due to its
side effect profile that includes depression and parkinsonism [1]. In
2017, valbenazine and deutetrabenazine were FDA approved for the
treatment of tardive syndrome. Valbenazine and deutetrabenazine
are VMAT‐2 inhibitors and derivatives of tetrabenazine designed to
increase the half‐life and decrease fluctuations in plasma levels. These
pharmacokinetic changes were targeted in hopes to reduce the fre-
quency of adverse effects while providing consistent movement
control.
In phase 3 randomized, double‐blind, placebo‐controlled trials for
both valbenazine and deutetrabenazine, the side effect profile was lim-
ited primarily to somnolence, akathisia, and dry mouth, with no
reports of drug induced parkinsonism (DIP) from valbenazine in the
KINECT 3 trial, one patient identified with DIP in the KINECT 3 exten-
sion (Factor et al. (2017). J Clin Psychiatry), and only one case of DIP
from deutetrabenazine the AIM‐TS trial [2,3]. In this paper, we report
two cases of VMAT2 inhibitor induced DIP: one associated with valbe-
nazine and one with deutetrabenazine.
2. Case 1
A 59‐year‐old man treated for depression with valproic acid for
about 10 years was being switched to aripiprazole (15 mg/day) in
2015. On examination in 2017, he had only stereotypical movements
involving tongue, mouth, face and head regions, cervical dystonia and
blepharospasm (AIMS‐TD score 12). Aripiprazole was stopped within a
month of onset of TS symptoms. In May of 2018, deutetrabenazine was
started for TS and titrated to 21 mg twice a day. Within a few weeks,
the TS symptoms had improved, but the patient complained of somno-
lence and dizziness. These effects persisted even after reduction of the
dose to 12 mg twice a day. Tapering further to 6 mg qAM and 12 mg
qPM resolved the somnolence and dizziness, but TS reappeared.
Deutetrabenazine was changed to valbenazine 80 mg daily. With this
dose, he had somnolence and therefore, the dose was decreased to
40 mg daily. In the next 2 months of initiation of this medication,
TS symptoms significantly improved but the patient presented with
right hand resting tremor and slow walking, and on examination he
had asymmetrical parkinsonism (MDS‐UPDRS III score: 18). Patient
preferred to continue valbenazine at 40 mg/day despite the Parkinso-
nian symptoms for his TS. With slow progression of parkinsonism, car-
bidopa/levodopa 25/100 mg 1 tab by mouth three times a day was
added, and the patient initially reported significant improvement in
his parkinsonism and continued to have improvement in TS. On
follow‐up, his tremor had returned and his DAT scan showed
decreased uptake in his right putamen. Please see the attached DAT
scan image below.
3. Case 2
An 86‐year‐old woman with gastroparesis who was on metoclo-
pramide for twenty years presented with involuntary tongue move-
ments for 6 months. Metoclopramide was immediately stopped, and
the involuntary movements worsened to involve the trunk too. On
examination in August of 2019, she had oro‐bucco‐lingual movements
and truncal dyskinetic movements s/o TS (AIMS‐TD score 14). She was
started on deutetrabenazine and the dose was titrated to 18 mg twice a
day. In the next 6 weeks, TS was significantly improved but she com-
plained of slowness of spontaneous movements, along with a masked
face and low‐pitched voice. On examination in October 2019, she was
noted to have symmetrical parkinsonism (bradykinesia‐rigidity pre-
dominant) and the dose of deutetrabenazine was decreased to
12 mg twice a day. Within a few weeks, parkinsonism has resolved
and continued to have significant improvement of TS. Patient refused
a DAT scan.
4. Discussion
We report two cases of VMAT‐2 inhibitors induced Parkinsonism of
which one of them is a man in whom we propose that the underlying
Parkinson’s disease (based on decreased uptake in right putamen and
clinical presentation) was unmasked secondary to newly introduced
dopamine‐depleting medication. In case 1, we added carbidopa/levo-
dopa to manage DIP symptoms as the patient was experiencing a sig-
nificant benefit from valbenazine. In Case 2, we still consider one of
the two possibilities of either unmasking the underlying Parkinson’s
disease (more likely) or a Drug induced Parkinsonism secondary to
deutetrabenazine as we couldn’t get a DAT scan for more definitive
answer. To access the video of both the patients exhibiting signs and
symptoms of Parkinsonism, click on the image below (online version
only).
Based on the review of literature to‐date there has been only one
article that addressed valbenazine‐induced parkinsonism, our cases
demonstrate a similar side effect profile [4]. There are no comparator
trials between these medications and this adverse effect is relatively
https://doi.org/10.1016/j.prdoa.2020.100078
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rare so it is not advised to compare the results of these clinical trials
for prevalence or severity. Per the prescribing information, the fre-
quency of Parkinsonism for valbenazine is 3% and less than 1% in
those who received placebo. One of 221 patients treated with
deutetrabenazine in the AIM‐TS trial was reported to develop Parkin-
sonism. With tetrabenazine, 10% prevalence of Parkinsonism was
reported in 48 week open label study. Valbenazine and deutetra-
benazine are considered as first line choices of pharmacotherapy for
TS [5] but are not devoid of unmasking of underlying PD or DIP.
The clinicians should be cautious and maintain a high index of clinical
suspicion for DIP, in individuals treated with newer generation
VMAT2 inhibitors, irrespective of the dose.
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